Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "novel transcript, antisense to CD97" (ENSG00000267379) is a long noncoding RNA (lncRNA) gene identified in the human genome and is transcribed antisense to the CD97 coding gene. Antisense transcripts such as this can regulate expression of their corresponding sense gene (in this case, CD97) by mechanisms including chromatin modification, transcriptional interference, and modulation of transcript stability[2][5][10][11]. Although widespread and functionally important as a type of gene expression regulatory RNA, these transcripts are not typically considered classical therapeutic targets such as receptors or enzymes, and no drugs are reported to directly interact with this particular transcript. Antisense lncRNAs have emerged as significant in fine-tuning cellular processes, but specific molecular and disease roles for ENSG00000267379 remain largely uncharacterized, with suggestive links to immune cell contexts due to CD97 function[4][1].
Not applicable. As a noncoding RNA, it is not directly targeted by drugs; experimental approaches have used antisense oligonucleotides to modulate the function of other NATs, but not specifically this one
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to CD97 (None).